Although c-Kit is highly expressed in Brca1 mutant mammary tumors (Regan et al., 2012, Smart et al., 2011), as well as in a subset of breast cancers within the TNBC group (Jansson et al., 2014), targeting this receptor has not been an effective therapeutic approach (Yardley et al., 2009). Here, KIT is linked to breast carcinoma.